Corvus Pharmaceuticals, Inc. — Director's Dealing 2024

Dec 23, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2024-12-20

Reporting Person: Arcara Jeffrey (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-20	Stock Option (Right to Buy)	$4.99	A	50000	Acquired	2034-12-20	Common Stock (50000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.